Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptimizeD Pilot Study
NCT06153004Phase 3Completed
- Sponsor
- Harvard Medical School
- Start
- Aug 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluoxetine in major depressive disorder (MDD) (2 arms), sponsored by Harvard Medical School. Primary endpoints: Feasibility as measured by recruitment rate at 3 months, Feasibility as measured by retention rate at 3 months and 2 more. Started Aug 2023; status: completed.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06153004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153004.